Redmile Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Redmile Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-152,000	Closed	-$14.2M	–	74
2017 Q2	$14.2M	Buy	+152,000	New	+$9.3M	0.87%	41
2016 Q2	–	Sell	-600,000	Closed	-$11.5M	–	59
2016 Q1	$11.5M	Buy	+600,000	New	+$12.7M	1.18%	26
2014 Q4	–	Sell	-100,000	Closed	-$4.54M	–	64
2014 Q3	$4.54M	Buy	+100,000	New	+$4.18M	0.52%	46

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Redmile Group's CLVS Position: Q2 2020 in Review

Redmile Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2020, closing a stake of 99,485 shares — an estimated $633K sold.

Redmile Group first reported a position in CLVS in Q2 2013 and held it in 26 quarters. The position peaked at $113M in Q1 2019. 158 funds tracked by Wall St. Rank hold CLVS as of Q2 2020.

Redmile Group reported no remaining Clovis Oncology, Inc. position as of Q2 2020 after selling out during the quarter.
Redmile Group sold 99,485 Clovis Oncology, Inc. shares in Q2 2020, an estimated $633K.
Redmile Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 26 quarters.
Redmile Group's Clovis Oncology, Inc. position peaked at $113M in Q1 2019.
158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2020.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.